Cliente: Biogen Local: Vila Olímpia, São Paulo-SP
Steven Leach Group has designed the new offices of Biogen located in Tokyo, Japan. Tokyo’s Nihonbashi district, a key business area within central Tokyo,
Biogen Idec Inc. (NASDAQ:BIIB) Seasonal Chart
Check out this week's trend profile of Biogen Inc. $BIIB - complete with future returns (%) expectations estimates!
Read More About Biogen Shortens Its Name And Expands Ambitions In Alzheimer's Treatments
Breaking Wave is an anamorphic kinetic sculpture created for our new headquarters in Cambridge, MA by Plebian Design and Hypersonic. If you’d like to visit i...
The pharmaceutical company's early drug trial aimed at combatting the disease had positive results. If future trials are successful, the drug could be a huge money-maker.
'Invisibles' is an awareness campaign to make visible all the lives behind Spinal Muscular Atrophy (SMA), a highly disabling rare neurodegenerative disease. The challenging reality of SMA patients is invisible to most of society. But there are many more people behind someone with SMA. Lives whose invisible work makes it possible for patients to lead a better life.
Reimagine MySelf™ encourages women with RMS to make small, but impactful changes through first-of-its-kind program on SELF.com
Graphic Design, Packaging, Adobe Photoshop, Adobe Illustrator
Your workout can be extra — your protein doesn’t need to be. Plant-based with 16g pea protein Keeps you feeling light and ready to move Only 4g sugar IngredientsCoconut cream, pea protein, almond milk, cocoa powder, sunflower lecithin, salt, monk fruit juice concentrate, cane sugar, gellan gum, natural flavors. Nutriti
Ivory, rust, white, black
When Aduhelm’s prospects appeared dead, Biogen mounted a secret campaign to resurrect the drug and convince the FDA to approve it.
Framesi Milan Biogen
In July, drugmakers Biogen and Eisai announced positive results to its experimental Alzheimer's drug, known as BAN2401. It was the first time in years that the pharmaceutical industry has had a positive Alzheimer's trial, and the news sent Biogen skyrocketing.
Experts are questioning a major scientific theory of the disease, which could mean two Biogen drugs won’t be successful.
I was a patient in the controversial Biogen clinical trial that drew so much attention to the CTAD conference. Here are my thoughts on the latest data.
A positive test could help you get your affairs in order and plan your future. And a drug company, Biogen, claims to have the first treatment that may slow the course of the disease if begun early enough.
On Mar 21, 2019, Biogen announced that the anti-amyloid antibody aducanumab failed futility analyses in two identically designed phase 3 Alzheimer's disease trials, and discontinued its development. However, on Oct 22, 2019, Biogen made the surprise announcement that they were applying for US Food and Drug Administration (FDA) marketing approval of aducanumab. The company explained that they reanalysed data from the trials to include patients who had continued in the studies from the Dec 26, 2018, cut-off date for the futility analyses to Mar 21, 2019, when futility was announced.
In afternoon trading on Thursday, Healthcare stocks are the worst performing sector, showing a 1.7% loss. Within the sector, Biogen Inc (NASD: BIIB) and Endo International plc (NASD: ENDP) are two of the day's laggards, showing a loss of 5.5% and 4.3%, respectively. Among healthcare ETFs, one ETF following the [...]
